Interesting clue to note that receivables as of Q1 stood at 544 million. We also know that the vaccine business took off from March onwards so the added revenue generated in Q2 will be quite significant on top of the outstanding receivables. Receivables are basically incoming revenue that will be recognised in Q2 once delivered and invoiced to the customer. Based on the above information, its reasonable to expect revenue for Q2 to exceed well over 1billion (it was 793 million in Q1). Earnings should hit around 35 plus million or thereabouts (compared to 23 million in Q1). So on top of the huge receivables of 544 million which will translate into revenue in Q2, we expect pharma to do another 600 million plus in business to hit the 1b revenue mark. Earnings of 35 million will translate into around 13 sen eps, compared to the Q1 eps of 8 sen. This is a conservative estimate because I am just basing on vaccine additional business and not assuming the non vaccine business growth. Biggest clue to knowing if a company's revenue will grow qoq is to compare the company's receivables qoq to see if its growing or decreasing. In Pharma case, receivables have shot up (320mill in q4 vs 544 million in Q1). We can look forward to an excellent Q2 and even better q3. Not to mention the bonus issue 4 for 1 which will goreng the share price in the run up to ex date. My sifu has predicted pre adjusted price of rm11 to 12 by ex date. At current prices, its considered a bargain after the heavy retracement. Let's not forget only 4% of Malaysians have been vaccinated thus far!
I'm stuck at 6.01 but my Bursa Saham economist friend advices me to keep for few more weeks, should have recovery. Of cos, this is her opinion. I'm newbie. This is my first time buy share.
Boustead disposed 1.6mil share, LTAT disposed >2mil share. dont know is it use to jack up the price or not. can see now the game is different way of playing.
Don't be so childish. Sinovac is already appointed pharma as distributor for Malaysia. and Malaysia req NPRA license to sell any medicine in Malaysia. That's something like SIRIM registed for consumer product. Vaccine contract is buying through gorv signed contract, You think pasar malam ah, Today want 1 mil dose only go to nego which one is cheap then buy which brand ah? some more, according to last few weeks news, pfizer and even sinovac and AZ already mentioned that 3rd dose is required after 12 months of 2nd dose. so far, vaccine business is still bright. Looking for Sinovac so far performance is with PAR, at least their business is granted before next election ( thats the reason pharma should make as much as possible in short term?)
There are always tense political ties between Malaysia and China, but the fact is we need China as a trade partner. I guess its just storm in the teacup, will always have goods from China
both big boss transfer out +-2mil share for what reason? must be doing something. I guess, they are press up the price. in the middle of way, u buang, they sapu also. in case accidently they collect enough 90%, they even can recall the share and reauirest de-list. then only declare the real profit. Just a guess only. You can see the selling part volume is not small. but very fast bought by ppl. and trade vol in 1 hr already 5mil.
It won't go down like last week because all the culling has already been done. Nobody will be letting go their tickets now. Let the sharks buy at higher prices
We can't stop them, just like esos, sis, private placement. As long as not at big discount and not big issuance as to cause big dilution, that is normal
New IPO: The largest mini-market player and a leading groceries retailer in Malaysia, 99 Speed Mart Retail Holdings Bhd aims to list on the Main Market!
MQ Trader 372 views | 2 d ago
0:17
New IPO: An enterprise IT solutions provider that provides implementation services, maintenance, support and professional services, Vetece Holdings Bhd aims to list on the Ace Market!
MQ Trader 521 views | 6 d ago
0:17
New IPO: A manufacturing and trading of biomass fuel products, particularly PKS and wood pellets company, Elridge Energy Holdings Bhd aims to list on the Ace Market!
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
Powerplay666
1,023 posts
Posted by Powerplay666 > 2021-06-07 19:43 | Report Abuse
Interesting clue to note that receivables as of Q1 stood at 544 million. We also know that the vaccine business took off from March onwards so the added revenue generated in Q2 will be quite significant on top of the outstanding receivables. Receivables are basically incoming revenue that will be recognised in Q2 once delivered and invoiced to the customer. Based on the above information, its reasonable to expect revenue for Q2 to exceed well over 1billion (it was 793 million in Q1). Earnings should hit around 35 plus million or thereabouts (compared to 23 million in Q1). So on top of the huge receivables of 544 million which will translate into revenue in Q2, we expect pharma to do another 600 million plus in business to hit the 1b revenue mark. Earnings of 35 million will translate into around 13 sen eps, compared to the Q1 eps of 8 sen. This is a conservative estimate because I am just basing on vaccine additional business and not assuming the non vaccine business growth.
Biggest clue to knowing if a company's revenue will grow qoq is to compare the company's receivables qoq to see if its growing or decreasing. In Pharma case, receivables have shot up (320mill in q4 vs 544 million in Q1).
We can look forward to an excellent Q2 and even better q3. Not to mention the bonus issue 4 for 1 which will goreng the share price in the run up to ex date.
My sifu has predicted pre adjusted price of rm11 to 12 by ex date.
At current prices, its considered a bargain after the heavy retracement. Let's not forget only 4% of Malaysians have been vaccinated thus far!